Raymond James Financial Inc. Acquires New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 70,826 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,916,000. Raymond James Financial Inc. owned approximately 0.34% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares during the period. abrdn plc bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $13,155,000. Bank of Montreal Can bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $13,043,000. Barclays PLC grew its stake in ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after buying an additional 135,003 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in ANI Pharmaceuticals by 67.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company’s stock worth $17,226,000 after purchasing an additional 125,438 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $67.17 on Thursday. The business’s 50 day moving average is $60.09 and its two-hundred day moving average is $58.24. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -122.13 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.31.

Insider Buying and Selling

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,200 shares of company stock valued at $191,776. Corporate insiders own 12.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ANIP. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 target price for the company. Finally, StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $79.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.